Ligand Pharmaceuticals, Inc.
LGNZZ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.4M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.40 Million |
|---|---|
| Enterprise Value | $-229,766,660.00 |
| Earnings per Share | $6.44 |
| Beta | 0.98 |
| Outstanding Shares | 19,962,000 |
Return
| Return on Equity | 2.09% |
|---|---|
| Return on Assets | 0.93% |
| Return on Invested Capital | 5.74% |
Valuation & Multiples
| P/E Ratio | 0.03 |
|---|---|
| PEG | -0.02 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 24.44 |
| Enterprise Value to EBIT | 50.56 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 29, 2026
EPS Estimate
$2.33
Consensus analyst estimateRevenue Estimate
$77.00 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$2.31
Consensus analyst estimateRevenue Estimate
$77.95 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Ligand Pharmaceuticals, Inc.
47 employees
CEO: John Higgins
Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its...